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Abstract
Therapeutic angiogenesis, that is, the generation of new vessels by delivery of spe-
cific factors, is required both for rapid vascularization of tissue-engineered con-
structs and to treat ischemic conditions. Vascular endothelial growth factor (VEGF)
is the master regulator of angiogenesis. However, uncontrolled expression can lead
to aberrant vascular growth and vascular tumors (angiomas). Major challenges to
fully exploit VEGF potency for therapy include the need to precisely control in vivo
distribution of growth factor dose and duration of expression. In fact, the therapeu-
tic window of VEGF delivery depends on its amount in the microenvironment
around each producing cell rather than on the total dose, since VEGF remains
tightly bound to extracellular matrix (ECM). On the other hand, short-term expres-
sion of less than about 4 weeks leads to unstable vessels, which promptly regress
following cessation of the angiogenic stimulus. Here, we will briefly overview some
key aspects of the biology of VEGF and angiogenesis and discuss their therapeutic
implications with a particular focus on approaches using gene therapy, genetically
modified progenitors, and ECM engineering with recombinant factors. Lastly, we
will present recent insights into the mechanisms that regulate vessel stabilization
and the switch between normal and aberrant vascular growth after VEGF delivery,
to identify novel molecular targets that may improve both safety and efficacy of
therapeutic angiogenesis.
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1 | INTRODUCTION
Blood vessel growth is an integral process in regenerative medicine.
Vascular regulation is also key for the repair of naturally avascular tis-
sues such as cartilage, where inhibition of angiogenesis has been
shown to favor the spontaneous chondrogenic differentiation of pro-
genitors in vivo.1 Focusing only on the situations where new vascular
induction is required, two main areas of therapeutic interest can be
conceptually distinguished: (a) the expansion of pre-existing vascular
networks in ischemic tissues to restore blood flow and salvage func-
tion (therapeutic angiogenesis); and (b) the rapid de novo vascular
invasion of engineered grafts to enable progenitor survival and
differentiation.Roberto Gianni-Barrera and Nunzia Di Maggio contributed equally to the study.
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Ischemia is caused by an inadequate blood supply for tissue
demand. The most prevalent cause is progressive atherosclerotic
stenosis of cardiac or limb arteries (coronary or peripheral artery dis-
ease, respectively; CAD and PAD), which can be compounded by
microvascular dysfunction in metabolic syndromes such as diabetes.
The consequences of CAD range from chest pain upon exertion
(angina) to myocardial infarction and end-stage heart failure,
whereas PAD leads to progressive muscle pain with walking
(claudicatio), skin ulcerations, and necrosis, necessitating amputa-
tion. Impaired wound healing in diabetic patients, especially of the
foot, can have dire consequences through infection and necrosis.
Together with their high prevalence in western-style societies, car-
diovascular ischemic diseases pose a heavy social and economic bur-
den, due to early mortality, impaired quality of life with pain and loss
of mobility, and recurrent hospitalization.2 Current treatments for
CAD and PAD mainly include endovascular procedures such as bal-
loon angioplasty/stenting and bypass surgery or possibly exercise
training for limb ischemia. However, many patients with end stage
CAD or PAD are not candidates for such procedures due to a lack of
target vessels. On the other hand, standard treatment of diabetic
foot ulcers is purely supportive.3 Therapeutic angiogenesis, that is,
the generation of new vascular networks through delivery of spe-
cific growth factors, is an attractive strategy to restore perfusion to
ischemic tissues and fill this unmet clinical need.
Another area of regenerative medicine in which vascular
growth plays a key role is the vascularization of tissue-engineered
grafts.4 In particular, bone replacement is required in several situa-
tions due to trauma, surgery, or idiopathic conditions such as avas-
cular necrosis of small bones, where spontaneous regeneration is
insufficient. Bone tissue-engineering holds promise for the genera-
tion of osteogenic grafts, combining osteo-progenitors with bio-
compatible scaffolds.5,6 However, for defects of clinically relevant
size, the lack of rapid vascularization in vivo causes severe ischemia
and progenitor death in the graft core deeper than 1 to 2 mm.7 Sim-
ilar biological principles apply to the vascularization of both ische-
mic tissue and engineered grafts, but with different translational
considerations.
2 | BIOLOGICAL BASES OF THERAPEUTIC
VASCULARIZATION
After the discovery of vascular endothelial growth factor (VEGF), first
as a permeability factor in 19838 and then as an endothelial mitogen
in 1989,9,10 intense investigations began into the new concept of
therapeutic angiogenesis, aiming at restoring the blood supply in
ischemic tissues by growing new blood vessels with VEGF and later
other angiogenic factors. Positive preclinical and early clinical evi-
dence seemed to indicate great potential for this strategy. However, a
decade of subsequent controlled clinical studies showed that the sim-
ple delivery of the VEGF protein or gene to ischemic tissue has no
clear efficacy at safe doses.11 The disappointing clinical results are a
stark contrast to the fundamental biological role of VEGF as the
master regulator of vascular growth. In fact, VEGF kicks off the com-
plex cascade of cellular and molecular events leading to the orderly
assembly of new endothelial structures (morphogenesis), their associ-
ation with mural cells/pericytes (maturation), and subsequent ability
to persist indefinitely in the absence of further growth factor signaling
(stabilization), to form fully functional vascular networks.12 Therefore,
a better understanding of the physiological mechanisms of vascular
growth is important to exploit its therapeutic potential. Here, we will
address some key aspects of the biology of VEGF and angiogenesis,
and their therapeutic implications.
2.1 | VEGF and its gradients
The mammalian VEGF family comprises five main ligands (VEGF-A, -B,
-C, and -D and placenta-derived growth factor, PlGF) and three recep-
tors (VEGF-R1, -R2, and -R3). Although the principal role of VEGF-C
and -D is to stimulate lymphatic angiogenesis through VEGF-R3,
blood vessel growth is mostly coordinated by the signaling of VEGF-A
and -B and PlGF through R1 and R2 (for a comprehensive review, see
reference 13). Despite the multiplicity of players, the molecular target
for therapeutic angiogenesis is essentially VEGF-A signaling, as VEGF-
B and PlGF play more accessory or tissue-specific roles.14 We will
refer to VEGF-A simply as VEGF throughout the manuscript.
An important feature of VEGF function, with widespread therapeu-
tic implications, is its interaction with extracellular matrix (ECM), which
dictates its spatial localization in tissues and regulates the outcome of
the angiogenic process. In fact, alternative mRNA splicing of the Vegfa
transcript gives rise to three major isoforms with different degrees of
affinity for the ECM.15 These comprise 120, 164, and 188 residues in
rodents (or 121, 165, and 189 in humans, respectively) due to the pres-
ence or absence of heparin-binding domains that interact with ECM
proteoglycans, so that matrix affinity is very low in the shortest isoform
and increases with molecular size.16 The isoforms also display differ-
ences in their signaling. In fact, VEGF164/165 binds the coreceptor
Neuropilin-1 (Nrp1), enhancing activation of VEGF-R2 and endothelial
proliferation and migration, whereas VEGF120/121 does not.
17 Further-
more, a distal splice site in the last exon of the VEGF gene can give rise
to a second set of “b” isoforms, which differ only in the sequence of the
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last six residues and are therefore named VEGFxxxb. However, contrary
to the classic isoforms, the b variants are antiangiogenic and provide a
further layer of regulation to the angiogenic balance in tissues.18 As a
consequence of differential matrix binding, VEGF120/121 is highly diffus-
ible in tissues, VEGF188/189 remains extremely localized at the site of
secretion and VEGF164/165 instead generates intermediate gradients of
concentration around the producing cells. The importance of differential
matrix affinity of VEGF isoforms was shown elegantly in transgenic
mice selectively producing only one isoform from the endogenous
locus, so that regulation of expression was not altered.19 Diffusible
VEGF120 induced malformed vessels, which were aberrantly enlarged
and lacked branching, whereas vessels generated by sticky VEGF188
showed opposite defects, with very small diameters and hyper-
branching. VEGF164 was the only isoform capable of inducing physio-
logical vascular networks in the absence of the other ones, thanks to its
intermediate matrix affinity. It should be noted that the key requirement
for physiological VEGF function is a balance between diffusibility and
binding, rather than a specific isoform. In fact, normal vascular morpho-
genesis also took place in the absence of VEGF164, as long as VEGF120
and VEGF188 were both expressed. The importance of balanced matrix
affinity therefore makes VEGF164/165 the isoform of choice for thera-
peutic delivery.
2.2 | Cellular mechanisms: Sprouting and
intussusception
Sprouting is the best characterized cellular mechanism of angiogenesis
and is the primary process by which new vessels grow out of pre-
existing ones to invade surrounding tissue, for example, during embry-
onic development, endochondral ossification, menstrual decidua
regeneration, or tumor vascularization. Sprouting entails the specifica-
tion of endothelium into two functionally distinct phenotypes, that is,
tip and stalk cells, and is guided by the formation of VEGF concentra-
tion gradients.20 The first endothelial cell reacting to VEGF becomes a
tip, which extends numerous thin filopodia from the basal side into
the surrounding matrix to sense the gradient and migrates toward its
source (Figure 1A). Each tip cell instructs its neighboring cells to
acquire the stalk phenotype and these proliferate to form the new
vessel trunk (Figure 1B). Interestingly, while tip cells respond to the
gradient of VEGF distribution, stalk cell proliferation is regulated by
its absolute concentration.20 Finally, to form a functional network the
tip cells of two vascular sprouts first make filopodia contacts with
each other, then fuse and finally form a new continuous perfused
lumen through a complex series of cellular rearrangements21
(Figure 1C). Tip cell fusion can also be promoted by macrophages,
which act as chaperones between the contacting filopodia22
(Figure 1B). The balanced formation of tip and stalk cells is finely regu-
lated by Dll4/Notch1 signaling, whereby the first endothelial cell sens-
ing the VEGF gradient becomes a tip by default and upregulates the
ligand Dll4. This activates Notch1 on the neighboring cells, which are
so instructed to downregulate both VEGF-R2 and Dll4 expression and
acquire a stalk phenotype, through a mechanism of lateral inhibition.23
Disturbance of Notch1 signaling causes excessive tip cell formation
and increased sprouting, which, however, is accompanied by impaired
stalk cell generation and therefore leads to nonfunctional endothelial
structures that have no lumen and are not perfused.23
Vascular network expansion can take place also by the alternative
mechanism of intussusception (from the Latin meaning “growth within
itself”), also referred to as splitting angiogenesis.24 Intussusception can
be initiated very rapidly by increased blood flow and shear stress in the
absence of growth factors,25 but it can also follow VEGF upregulation.26
It is still unclear what determines whether VEGF induces sprouting or
angiogenesis, but its distribution in matrix is likely to play a role and the
absence of a concentration gradient appears to favor intussusception.
For example, both outcomes have been described in skeletal muscle:
spontaneous upregulation of VEGF by ischemia leads to sprouting,27 but
its over-expression at significantly higher and therapeutic levels, which
saturate the little matrix between fibers and abrogate local gradients,
causes angiogenesis by intussusception.26 Contrary to sprouting, no tip
cells are formed and activated endothelial cells respond exclusively by
proliferation without migration, leading first to circumferential enlarge-
ment of the vessel (Figure 1D,E), which then splits longitudinally into
new daughter vessels. Splitting requires the formation of tissue pillars
across the vascular lumen. These can form through two alternative pro-
cesses: (a) a vascular wall invagination that creates a contact between
the opposite endothelial cells28 (Figure 1F), or (b) the extension and
fusion of intraluminal filopodial-like protrusion from the endothelium29
(Figure 1G,J,K). Subsequently, the endothelial junctions reorganize and
myofibroblast invade the core, stabilizing the structures into mature
transluminal tissue pillars (Figure 1H,L,M). Finally, these align along the
length of the vessel, fuse together, and divide the affected vascular seg-
ment longitudinally (Figure 1I).
In recent years, it has become increasingly clear that intussuscep-
tion is a therapeutically important mechanism of angiogenesis.12,26,30
The molecular regulation of intussusception is still poorly understood
and likely quite different from that of sprouting. Inhibition of Notch
signaling in the absence of growth factor delivery has been described
to stimulate intussusceptive vascular expansion in the chicken chorio-
allantoic membrane31 and in the mouse liver.32 On the other hand,
recent data show that the outcome of VEGF-induced intussusceptive
angiogenesis can be modulated by pericyte recruitment by platelet-
derived growth factor-BB (PDGF-BB)33 and stimulation of endothelial
EphB4 signaling by pericyte-expressed ephrinB2.34
2.3 | PDGF-BB and the pericyte-endothelium
crosstalk
After endothelial assembly, new microvascular networks need to
undergo maturation by associating with pericytes. This important cell
type has exquisitely regulatory functions and provides signals that
switch off endothelial proliferation and permeability and make the
new vessels stable, that is, independent of continued VEGF stimula-
tion and able to persist indefinitely after the angiogenic signals sub-
side. Pericytes are recruited by PDGF-BB secreted by activated
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endothelium and interference with this process is incompatible with
embryonic development, leading to sustained endothelial prolifera-
tion, vessel wall fragility, and lethal bleeding.35,36 PDGF-BB function
also critically relies on its interaction with ECM and gradient forma-
tion. In fact, removal of its matrix-binding domain leads to pericyte
detachment from nascent vessels and severe vascular dysfunction.37
F IGURE 1 Sprouting and intussusception: two alternative modes of angiogenesis. Schematic representation of the processes generating new
vascular structures by sprouting (A–C) or by intussusception (vascular splitting; D–I). J–M, Immunofluorescence images of vessels undergoing
intussusception after vascular endothelial growth factor delivery in murine skeletal muscle, stained for endomucin (endothelial cells, green),
laminin (basal lamina, red), and with DAPI (nuclei, blue). Circumferentially enlarged vessels displayed: (a) no degradation of the basement
membrane; (b) intraluminal filopodia-like protrusions from the endothelial layer (white arrowheads in high-magnification panels K and M); and
(c) mature intraluminal tissue pillars (white arrows in high-magnification panel M). * represents vascular lumen; scale bars = 20 μm in all panels
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Pericytes regulate endothelial function through both paracrine and
cell contact-dependent signals. The principal pathways mediating this
molecular crosstalk are transforming-growth factor-β1 (TGF-β1),
angiopoietins-1 and -2 (Ang-1 and Ang-2), and ephrinB2/EphB4.38 TGF-
β1 is produced in a latent form and its activation requires cell-to-cell con-
tact between endothelial and mural cells through proteolytic cleavage of
the latency-associated peptide by plasmin at the vessel wall interface.39
TGF-β1 regulates both the endothelium and pericytes and can promote
contrasting functions, depending on alternative Alk1 and Alk5 receptor
stimulation and downstream SMAD pathway activation.40 In fact, activa-
tion of Alk5-SMAD2/3 specifically promotes vascular stabilization by
inducing endothelial quiescence and stimulating the production of ECM
and basement membrane proteins.41 In contrast, activation of
Alk1-SMAD1/5 promotes endothelial cell proliferation and migration as
well as endothelial-to-mesenchymal transition.41
Angiopoietins are the ligands of the endothelium-specific tyrosine
kinase receptor Tie2. Ang1 is expressed by mural cells and activates
Tie2: it facilitates the further recruitment and association of pericytes
with newly formed vascular structures, acts as a survival signal for
endothelial cells and inhibits VEGF-induced vascular leakage.42 On
the other hand, Ang2 is a context-dependent partial agonist of the
Tie2 receptor, mostly acting as an inhibitor of its activation. It is stored
preformed in Weibel–Palade bodies of endothelial cells, from which it
is rapidly released upon VEGF stimulation. It plays a key role to initiate
the angiogenic process by promoting the dissociation of pericytes and
endothelial cells and allowing their formation of new vascular struc-
tures. However, it also promotes endothelial cell apoptosis and vascu-
lar regression if VEGF signaling is disrupted at this crucial stage.42
Eph receptors and ephrin ligands are both membrane-bound and,
therefore, binding and activation of Eph and ephrins requires cell–cell
contact. Characteristically, engagement of the Eph–ephrin system elicits
bidirectional signaling, that is, “forward signaling” in the cell expressing the
Eph receptor and “reverse signaling” in the cell expressing the ephrin
ligand.43 In tumor angiogenesis, activation of reverse signaling via the
EphB4 ligand ephrinB2 was shown to stimulate pericyte association to
blood vessels and inhibit their permeability through the activation of the
Ang1/Tie2 pathway.44 Conversely, in a tissue-specific mutant model,
ephrinB2-deficient pericytes failed to establish proper cell-to-cell contacts
with microvascular endothelium, leading to hemorrhaging and perinatal
mortality.45 EphrinB2 has also been shown to directly modulate VEGF-R2
and VEGF-R3 activation in sprouting tip cells by controlling their internali-
zation, necessary for receptor activation of downstream signaling.46,47
Recently, we also found that EphB4 activation also regulates splitting
angiogenesis independently of VEGF-R2 internalization or phosphoryla-
tion, but rather by modulating the activation of ERK1/2 downstream of
the receptor and the speed of endothelial proliferation.34
2.4 | Circulating monocytes
Besides endothelial and mural cells, different populations of circulat-
ing myeloid cells play a crucial role in both induction and maturation
of new vessels.48 CXCR4+ monocytes are recruited by VEGF
expression, do not incorporate into new vessels (unlike circulating
endothelial progenitors), but are retained in a perivascular position
through Stromal Cell-Derived Factor-1 (SDF-1)/CXCR4 signaling and
sustain vascular growth through further secretion of pro-angiogenic
factors.49 On the other hand, a similar CXCR4+ population of circulat-
ing monocytes has been recently shown to promote intussusceptive
vascular growth during liver regeneration by participating in the for-
mation and stabilization of intraluminal pillars.50 Tissue macrophages
also aid the completion of sprouting angiogenesis by promoting tip
cell fusion and anastomosis, acting as cellular chaperones.22 These
macrophages expressed both the surface receptors Tie2 and Neuro-
pilin1 (Nrp1) and therefore were phenotypically similar to the family
of pro-angiogenic Tie2-expressing macrophages (TEM). TEM have
been described as tumor-infiltrating myeloid cells that convey pro-
angiogenic signals and can provide a mechanism of resistance to anti-
angiogenic drugs, promoting cancer progression.51 A population of cir-
culating Neuropilin1-expressing monocytes (NEM) has been shown to
also stimulate vascular maturation and smooth muscle cell recruit-
ment. These cells coexpress CD11b and Nrp-1, which is a receptor for
both VEGF and Semaphorin-3A (Sema3A), are recruited at sites of
VEGF expression and promote the formation of arteries by the para-
crine actions of several factors such as Ang1, TGF-β, and PBGF-BB.52
We recently found that NEM are specifically recruited to angiogenic
sites by Sema3A produced by activated endothelium and accelerate
stabilization of newly induced microvascular networks, that is, their
ability to survive independently of VEGF signaling and persist
indefinitely.53
3 | THERAPEUTIC CONSIDERATIONS FOR
VEGF DELIVERY
3.1 | The control of dose distribution
Therapeutic use of VEGF requires careful dose control, as uncon-
trolled delivery has been shown to cause aberrant vascular growth
and angioma-like vascular tumors in muscle, heart and other tis-
sues.54-57 The physiological affinity of VEGF for ECM has significant
therapeutic implications for its dosing and delivery strategies. In fact,
upon VEGF gene delivery, it remains tightly localized in the microenvi-
ronment around each producing cell and different levels of expression
do not average with each other. Therefore, the therapeutic outcome
between safety and efficacy of factor delivery is determined by the
distribution of microenvironmental concentrations in tissue rather
than simply the total dose delivered. This concept is exemplified by
experiments in which the average and microenvironmental dose of
VEGF could be controlled independently by cell-based gene deliv-
ery.58 Different VEGF doses were expressed in skeletal muscle by
populations of genetically modified muscle progenitor cells (myo-
blasts). Random genomic integration of the viral vector leads to differ-
ent expression levels in each transduced cell. Implantation of this
heterogeneous population always leads to aberrant angioma-like vas-
cular growth, even if the total dose is reduced several-fold by dilution
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with nonexpressing cells. On the other hand, by isolating and expanding
single myoblasts it is possible to obtain monoclonal populations in
which every cell produces the same level. Under these conditions,
which ensure a homogeneous microenvironmental distribution of the
dose, it is possible to induce only normal and physiological angiogenesis
across a wide range of doses, as well as to effectively restore functional
blood flow in limb ischemia.59 In contrast, the same total doses are toxic
when delivered by dilutions of the heterogeneous population, because
rare hotspots of excessive production cannot be avoided.58
The need to control the distribution of microenvironmental doses is
key when addressing the therapeutic window of VEGF delivery. In fact,
when heterogeneous expression levels are generated in the tissue, such
as by direct delivery of gene therapy vectors, effective doses in some
microenvironments are accompanied also by ineffective and by toxic
levels in other areas. In order to ensure safety, the total vector dose must
be limited, but this increases the frequency of ineffective levels, thereby
jeopardizing efficacy (Figure 2A). As a consequence, the usable therapeu-
tic window of VEGF gene delivery appears to be very narrow.55 On the
other hand, VEGF does not have an intrinsically very steep dose–
response curve and its biological therapeutic window is much larger,58,59
but it is key to control the distribution of doses in the microenvironment
in vivo in order to exploit the therapeutic potential of VEGF delivery,
ensuring both safety and efficacy (Figure 2B).
Translating this concept poses a fresh set of challenges. In fact,
gene therapy is the preferred approach for therapeutic angiogenesis,
thanks to a very robust delivery potential and standardized GMP vec-
tor production, but it is extremely difficult to avoid heterogeneous
expression levels in vivo with uncontrolled vectors. Several groups are
actively developing new generations of vectors, for example, ones
that may self-regulate in the tissue,60 and investigating other improve-
ments in the gene therapy approaches: an excellent coverage of the
latest discoveries can be found in a recent review by Ylä-Herttuala
and Baker.61
3.2 | Cell-based gene delivery
The distribution of expression levels in vivo can be controlled by a
cell-based gene therapy approach. As detailed above, transduction of
a progenitor population with an integrating viral vector leads to stable
but heterogeneous expression levels in different cells. We developed
a fluorescence-activated cell sorting (FACS)-based technology to pre-
dict the level of transgene expression in single live cells and to purify
populations homogeneously expressing specific levels.62 The trans-
gene of interest (eg, VEGF) is linked in a bicistronic viral vector to a
nonfunctional truncated version of the lymphocyte-specific marker
CD8a, which acts simply as a membrane-localized reporter protein. In
this way, changes in the level of expression of VEGF are reflected by
a parallel change in cell-surface expression of CD8a, which can be
detected and quantified on live cells by FACS, enabling the purifica-
tion of specific populations homogeneously expressing different
VEGF levels (Figure 3). This technology can be used with different
progenitor classes63 for different applications. FACS purification of
VEGF-expressing myoblasts was shown to yield only normal and func-
tional angiogenesis in skeletal muscle,62,64 while purification of VEGF-
expressing adipose-derived stromal cells ensured controlled vascular
growth in the normal myocardium65 and prevented deterioration of
cardiac function in a model of myocardial infarction by limiting fibrotic
scarring.66
Cell-based VEGF gene delivery has also been investigated to pro-
mote the rapid vascularization of tissue-engineered grafts, for exam-
ple, for cardiac patches or bone regeneration. Differently from the
ischemic conditions described above, in these strategies, suitable pro-
genitors are seeded on appropriate scaffolds and need to rapidly
attract a vascular supply after in vivo implantation in order to differen-
tiate and function. It is therefore desirable to link the angiogenic signal
to the presence of the seeded cells by genetically engineering them to
produce VEGF. Cardiac patches engineered with FACS-purified
F IGURE 2 Functional outcomes of vascular endothelial growth factor (VEGF) dose distribution in tissue. A, Heterogeneous dose distributions
(eg, by gene therapy vectors) lead to hotspots of excessive expression that remains localized in the microenvironment around producing cells (red
spots, upper right panel) and lead to toxic effects. Reducing the total dose does not completely avoid toxic hotspots even if therapeutic levels are
achieved in some areas (blue spots, upper middle panel), until the total dose is so low that mostly ineffective levels are achieved (gray spots, upper
left panel). B, Homogeneous distribution of the total dose allows therapeutic levels (blue spots, upper middle panel) to be achieved and to harness
the therapeutic window of VEGF delivery
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VEGF-expressing myoblasts67 or adipose-derived stromal cells68 could
drive efficient vascularization of the patch itself and also provided
controlled VEGF release to induce extrinsic angiogenesis in the under-
lying myocardium.
VEGF-expressing human bone marrow osteoprogenitors could
effectively increase the vascularization of engineered bone grafts by
threefold, inducing physiologically structured vascular networks with
both conductance vessels and capillaries.69 However, sustained and
uncontrolled VEGF expression unexpectedly caused a global reduc-
tion in the quantity of bone, posing a challenge to its clinical applica-
tion. Progenitor engraftment or differentiation was not impaired, but
rather the recruitment of osteoclasts was strongly increased, thereby
disrupting bone homoeostasis toward excessive resorption. Current
research is aiming at decoding the crosstalk between angiogenesis
and osteogenesis, as well as ensuring that the two processes are ther-
apeutically coupled.
3.3 | Recombinant factor engineering for matrix
decoration
It is desirable to independently control the dose and duration of
angiogenic factor delivery in grafts. This is technically challenging with
gene transfer, while protein delivery suffers from short half-life
in vivo. Extensive efforts have generated many strategies to ensure
sustained release of recombinant growth factors from natural and
synthetic biomaterials. These approaches have been recently
reviewed by Browne and Pandit.70 However, it has also been possible
to create modified versions of growth factors by protein engineering,
so that they can be used to decorate natural matrices and be pres-
ented to cells in their physiological context during tissue regenera-
tion.71 The most ubiquitous and abundant ECM protein is collagen,
which is also employed as a basis for a variety of biomaterials. There-
fore, recombinant growth factors have been engineered with specific
collagen-binding domains, allowing their use to decorate collagen-
based biomaterials and prolonging their bioavailability and efficacy
(reviewed by Addi et al72). On the other hand, tissue regeneration
after damage starts in all cases with the deposition of a fibrin-based
matrix rich in growth factors,73 which provides ideal conditions for cell
migration, vascular invasion and progenitor differentiation. Therefore,
significant efforts have been directed at mimicking ECM decoration to
ensure physiological presentation of morphogens.
Growth factors have been incorporated into fibrin matrix exploi-
ting the coagulation process itself (Figure 4A, top). For example,
murine VEGF164 was fused to the octapeptide NQEQVSPL, which is
the substrate of the transglutaminase coagulation factor XIIIa,
allowing its covalent crosslinking into fibrin hydrogels and release only
by enzymatic cleavage.74 Further addition of the fibrinolysis inhibitor
aprotinin, also engineered with the same technology, could finely tune
the hydrogel degradation rate and therefore independently control
F IGURE 3 Fluorescence-activated cell sorting (FACS)-purification of genetically modified progenitor populations expressing homogeneous
vascular endothelial growth factor (VEGF) levels. A, Retroviral vector carrying a bicistronic cassette, in which the sequence of VEGF is linked to
that of the membrane-bound reporter CD8 through an Internal Ribosome Entry Site (IRES) sequence. B, Progenitors of interest are transduced
with this retroviral vector. C, After integration in the cell chromatin, the IRES sequence enables cotranslation of both proteins from the same
mRNA molecule. Therefore, the amount of CD8 on the cell membrane reflects that of secreted VEGF regardless of their absolute level of
expression. D, Transduced cells in the primary population express heterogeneous VEGF levels depending on their viral copy number and the
transcriptional activity of the chromatin integration sites. E, These can be FACS-sorted into homogeneous subpopulations stably expressing
specific VEGF levels based on the intensity of membrane CD8 staining
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the duration of factor release. Controlled VEGF delivery to skeletal
muscle through this optimized platform was shown to yield exclu-
sively normal, stable, and functional angiogenesis, over a wide range
of easily controllable doses, and restored blood flow to ischemic
tissues.75
The natural affinity of different ECM proteins for growth factors
can also be exploited (Figure 4A, bottom). For example, fibronectin
has binding sites for fibrin, integrins, and growth factors. By engineer-
ing a recombinant fibronectin fragment comprising all these sites, it
has been possible to codeliver the morphogens bone morphogenetic
protein-2 and PDGF-BB within a fibrin matrix to promote bone regen-
eration.76 Interestingly, presentation of the factors in their physiologi-
cal matrix context greatly increased their functional efficacy, ensuring
robust bone regeneration at very low and otherwise ineffective doses.
Taking a reverse strategy, a short domain found in placenta-derived
growth factor-2 was found to mediate broad binding to a wide variety
of ECM proteins. Engineering of any growth factor with this peptide
endowed them with super-affinity for ECM, thereby enabling the in
situ decoration of endogenous matrix with exogenously provided
therapeutic proteins77 (Figure 4B). The increased efficacy of the modi-
fied factors avoided the need to deliver supra-physiological doses of
VEGF, thereby increasing safety.
3.4 | Modulation of dose-dependent outcomes
An alternative class of approaches may help reduce the need to pre-
cisely control the distribution of VEGF doses in vivo. VEGF-A is a very
powerful activator of VEGF-R2 signaling, but alternative ligands have
been found to have milder activation profiles and therefore may
require less stringent dose control. The properties of VEGF-B might
particularly benefit applications to the cardiac muscle. In fact, VEGF-B
is specifically active in the myocardium, while it is poorly angiogenic in
other tissues.78 Furthermore, VEGF-B does not bind to VEGF-R2, but
rather activates it indirectly, by displacing inactive VEGF-A from
reservoir sites. Therefore, even robust over-expression of VEGF-B
does not easily lead to excessive VEGF-R2 signaling, because it is lim-
ited to the endogenous levels of VEGF-A for its action.79,80 Another
example is VEGF-D: in its native form it stimulates lymphatic angio-
genesis through VEGF-R3, but it can also generate a shorter form by
proteolytic cleavage of both the N- and C-termini, therefore named
VEGF-DΔNΔC. VEGF-DΔNΔC shifts its affinity to VEGF-R2 and stimu-
lates blood angiogenesis instead. However, because it has no heparin-
binding domain, it leads to a more diffuse distribution through ECM
and induces more physiological vascular growth than VEGF-A over-
expression.81 Clinical trials of therapeutic angiogenesis by adenoviral
delivery of VEGF-DΔNΔC are ongoing.82,83
The outcome of VEGF over-expression may also be significantly
modified by promoting pericyte recruitment. Studies in skeletal mus-
cle showed that the transition between normal and aberrant angio-
genesis is not determined exclusively by VEGF dose, but rather by the
balance between endothelial activation by VEGF and pericyte recruit-
ment by PDGF-BB.84 Codelivery of VEGF164 and PDGF-BB at a fixed
relative ratio, achieved through coexpression from a single bicistronic
vector, ensured the generation and long-term stability of exclusively
normal and functional microvascular networks regardless of absolute
VEGF dose,84,85 by limiting endothelial proliferation.33 Although
PDGF-BB alone does not induce vascular growth either in normal or
ischemic skeletal muscle,84,86 the beneficial effects of the VEGF/
PDGF-BB combination have been described in a variety of preclinical
settings, including gene delivery with adenoviral86 or adeno-
associated viral vectors,87 sustained release of the recombinant
factors from polymeric biomaterials88 or treatment with modified pro-
teins engineered for super-affinity to the ECM.77
As described above, pericytes exchange a complex molecular
crosstalk with endothelium and these signaling pathways can offer
more specific targets to regulate VEGF effects. For example, stimula-
tion of the Tie2 receptor by Ang1 has been shown to significantly
reduce the detrimental hyperpermeability and vascular leakage that
accompany VEGF stimulation.89 This therapeutic benefit can be
F IGURE 4 Strategies for matrix decoration with engineered recombinant factors. A, Fibrin matrices can be decorated with engineered growth
factors to mimic extracellular matrix (ECM) functions. Taking advantage of the coagulation cascade, an octapeptide substrate of the
TransGlutaminase factor XIII (TG hook) can be fused to growth factors (GFs), enabling their covalent crosslinking to fibrin. Specific domains of
ECM proteins (eg, fibronectin) can also be incorporated through a TG hook to exploit their natural affinity for different GFs. B, Endogenous ECM
can be decorated with therapeutic GFs engineered to exhibit super-affinity to a broad range of ECM components
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further compounded by the contemporaneous inhibition of Ang2.90
On the other hand, activation of endothelial EphB4 by ephrinB2 finely
tunes ERK1/2 phosphorylation downstream of VEGF-R2, thereby lim-
iting the rate of endothelial proliferation induced by VEGF.34 There-
fore, systemic treatment with recombinant ephrinB2-Fc was shown to
prevent aberrant angiogenesis by robust and uncontrolled VEGF
expression, without interfering with efficient normal microvascular
network formation.34
Although VEGF is the principal target for therapeutic
angiogenesis, the delivery of other factors has shown promising
preclinical results, such as the fibroblast growth factor (FGF) family
(FGF-1, FGF-2, and FGF-4) or hepatocyte growth factor, and clinical
studies are currently underway to evaluate their potential in coronary
or peripheral artery disease (CAD or PAD).61
3.5 | Duration of delivery and vessel stabilization
Another important consideration for the therapeutic effectiveness of
newly induced vasculature is its long-term persistence. In fact, while
new vascular networks are rapidly formed in a matter of few days
after VEGF delivery, they are initially unstable and will regress if VEGF
stimulation is withdrawn too early. Several lines of evidence in models
of inducible transgene expression91,92 or pharmacologic blockade58
support a need to sustain VEGF stimulation for about 4 weeks before
new vessels are stabilized and persist independently. This requirement
impairs the efficacy of transient VEGF gene delivery, for example, by
adenoviral vectors that have been widely used in clinical trials and
afford robust expression, but that are also cleared by the immune sys-
tem in about 10 days.93
More recently, we found that VEGF dose-dependently impairs
the kinetics of vascular stabilization, that is, vessels induced by lower
levels of VEGF stabilize faster. However, pericyte recruitment is not
affected. Rather, VEGF negatively regulates the production of
Sema3A by activated endothelium, which in turn impairs the recruit-
ment of Nrp1-expressing monocytes, activation of TGF-β1-SMAD2/3
signaling and the induction of endothelial quiescence.53 In a therapeu-
tic perspective, treatment with recombinant Sema3A was shown to
accelerate the stabilization of newly induced angiogenesis and allow
its persistence despite transient VEGF expression.53 Interestingly, the
stabilization of newly induced vasculature can also be promoted by
the mechanical properties (low stiffness) of a biomaterial environment,
through the recruitment of a novel population of mechano-sensitive
Piezo1+ monocytes.94
4 | CONCLUSIONS AND PERSPECTIVES
The biology of angiogenesis is complex and a better understanding of
its cellular and molecular mechanisms is necessary for the design of
rational and more effective therapeutic strategies. Therapeutic angio-
genesis in ischemic tissues and de novo vascularization of engineered
grafts present rather different requirements and therefore might be
best achieved by different approaches.
Tissue-engineered grafts are avascular upon implantation and
need to attract vascular in-growth. In order to rapidly guide sprouting
of new vessels and their migration toward the graft core, it is desirable
that the graft matrix presents an optimized microenvironment of
angiogenic cues. This can be achieved by predecorating a suitable
material (such as fibrin or collagen) with optimized doses and combi-
nations of engineered factors, as described above, or also by
employing decellularized ECM, enriched in morphogens by suitable
progenitor cell lines.95 The process can also be accelerated by
prevascularization, that is, preseeding with endothelial cells to gener-
ate self-assembling vascular structures inside the construct that can
anastomose with the penetrating host vessels.
On the other hand, ischemic tissues are already vascularized and
proangiogenic therapy aims at expanding the microvascular networks
to promote collateral artery remodeling and restore physiological
blood flow.13 For this, it is key to treat large volumes of target tissue
and gene delivery by viral vectors has a clearly superior efficacy com-
pared with both protein and cell-based approaches. For example, ade-
noviral vectors combine two clinically desirable features, namely
robustness of expression and transient duration, limited by the
immune response. However, these same features compromise safety
(by uncontrolled distribution of high levels) and efficacy (by regression
of unstable vessels). Based on recent advances in elucidating the
molecular regulation of the switch between normal and aberrant
angiogenesis and of vascular stabilization, as described above, it can
be envisioned that local delivery of VEGF-expressing adenoviral vec-
tors might be complemented by systemic treatment with drugs
targeting ancillary pathways (eg, EphB4 or Sema3A signaling), to
ensure a safe and effective outcome while exploiting the clinically
attractive features of VEGF gene therapy.
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